10173355PeptiLNP: A platform for designing and manufacturing targeted lipid nanoparticles for delivering genetic medicinesClosedFast Start ResponseInnovate UKOne of the biggest challenges with genetic medicines is delivering them to specific cells and tissues in the body. Approaches such as viral vectors, e.g. AAVs, can be effective but have drawbacks such as being limited to a single dose, having high immunogenicity and liver toxicity. Non-viral approaches are promising, and are known to be relatively safe following the billions of doses deployed during the COVID-19 pandemic. However, they still lack the ability to be targeted in the way the AAVs are able to achieve due to issues in the design process. Nanograb is addressing this issue by developing and deploying peptiLNP, a platform for designing and manufacturing targeted lipid nanoparticles (tLNPs). Nanograb will be creating tLNPs for the delivery of genetic medicines. These nanoparticles will be decorated to guide them to specific cells and tissues in the body. Nanograb is developing the software-hardware hybrid platform to design and manufacture nanoparticles for targeted gene delivery.